CA2484994A1 - Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes - Google Patents

Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes Download PDF

Info

Publication number
CA2484994A1
CA2484994A1 CA002484994A CA2484994A CA2484994A1 CA 2484994 A1 CA2484994 A1 CA 2484994A1 CA 002484994 A CA002484994 A CA 002484994A CA 2484994 A CA2484994 A CA 2484994A CA 2484994 A1 CA2484994 A1 CA 2484994A1
Authority
CA
Canada
Prior art keywords
seq
tgf
naturally occurring
amino acid
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002484994A
Other languages
English (en)
Other versions
CA2484994C (fr
Inventor
Jung San Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Louis University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2484994A1 publication Critical patent/CA2484994A1/fr
Application granted granted Critical
Publication of CA2484994C publication Critical patent/CA2484994C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à des procédés d'utilisation d'antagonistes peptidiques du TGF-bêta dans le but de faciliter la cicatrisation de plaies cutanées, notamment de brûlures, de lacérations et d'écorchures. L'administration à des plaies d'antagonistes peptidiques du TGF-bêta permet de réduire la formation de cicatrices, la contraction des plaies et le dépôt de composants matriciels extracellulaires, et elle permet également d'accroître les taux de ré-épithélialisation lors de la cicatrisation des plaies.
CA2484994A 2002-04-29 2003-04-15 Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes Expired - Lifetime CA2484994C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13594602A 2002-04-29 2002-04-29
US10/135,946 2002-04-29
PCT/US2003/011437 WO2003093293A2 (fr) 2002-04-29 2003-04-15 Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes

Publications (2)

Publication Number Publication Date
CA2484994A1 true CA2484994A1 (fr) 2003-11-13
CA2484994C CA2484994C (fr) 2016-06-14

Family

ID=29399231

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2484994A Expired - Lifetime CA2484994C (fr) 2002-04-29 2003-04-15 Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes

Country Status (4)

Country Link
EP (1) EP1534737A4 (fr)
AU (1) AU2003234734A1 (fr)
CA (1) CA2484994C (fr)
WO (1) WO2003093293A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723473B2 (en) 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
AU2005311098B2 (en) * 2004-12-01 2011-08-11 Allergan, Inc. Non-cytotoxic protein conjugates
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
EP3181580A1 (fr) 2006-11-02 2017-06-21 Acceleron Pharma Inc. Antagonistes des récepteurs alk1 et ligands et leurs utilisations
KR100879239B1 (ko) * 2007-04-19 2009-01-16 (주)케어젠 Ｔｇｆｐ－ｃａｐ 펩타이드 및 그의 용도
EP2192904B1 (fr) 2007-08-27 2016-08-17 Auxagen, Inc. PROCÉDÉS D'INHIBITION DE TGF-beta
EP3398966A1 (fr) 2008-05-02 2018-11-07 Acceleron Pharma, Inc. Procédés et compositions pour moduler l'angiogenèse et composition de péricytes
ES2337973B8 (es) 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
ES2330826B1 (es) 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. Sistema para empaquetamiento de adenovirus de alta capacidad.
EP2341913B1 (fr) 2008-09-16 2014-11-19 Saint Louis University Procédé d'amélioration de signalisation tgf-bêta
JP5611322B2 (ja) * 2009-04-14 2014-10-22 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. 形質転換成長因子の活性を有するペプチド及びその用途
CN102712933A (zh) 2009-11-05 2012-10-03 西马生物医学计划公司 调控的表达系统
WO2012001196A2 (fr) 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Vecteurs alphaviraux et leur utilisation pour l'expression de gènes hétérologues
EP2407534A1 (fr) 2010-07-14 2012-01-18 Neo Virnatech, S.L. Procédés et réactifs pour obtenir des particules virales actives du point de vue transcriptionnel et des virions recombinants
WO2013113755A1 (fr) 2012-01-30 2013-08-08 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Réactifs et méthodes utilisables en vue du traitement de maladies par inhibition de la voie de signalisation calcineurine-nfat
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
EP2878674A1 (fr) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Épisomes stables sur la base des vecteurs lentiviraux non intégratifs
WO2015101666A1 (fr) 2014-01-03 2015-07-09 Fundación Biofísica Bizkaia Vlp, procédés pour leur obtention et applications de ceux-ci

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423037A (en) * 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31

Also Published As

Publication number Publication date
WO2003093293A3 (fr) 2005-04-07
AU2003234734A8 (en) 2003-11-17
WO2003093293A2 (fr) 2003-11-13
CA2484994C (fr) 2016-06-14
EP1534737A4 (fr) 2007-10-31
EP1534737A2 (fr) 2005-06-01
AU2003234734A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
CA2484994C (fr) Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes
US20110008248A1 (en) Peptide Antagonists of TGF-Beta Family Members and Therapeutic Uses Thereof
EP0494264B1 (fr) Inhibition de facteur de croissance a transformation afin d'empecher l'accumulation de matrice extracellulaire
US6500431B1 (en) Inhibitors of angiogenesis and tumor growth
EP0527787B1 (fr) Procede destine a predisposer les mammiferes a la regeneration acceleree des tissus
Pignataro et al. Evidence for a protective role played by the Na+/Ca2+ exchanger in cerebral ischemia induced by middle cerebral artery occlusion in male rats
US8691944B2 (en) Fibronectin polypeptides and methods of use
JPH08510443A (ja) 生物学的に活性なＴＧＦ−β１およびＴＧＦ−β２ペプチド
US7060680B2 (en) Morphogen treatments for limiting proliferation of epithelial cells
JPH07504650A (ja) 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
WO1995022979A1 (fr) Methode de traitement de certaines pathologies de l'oeil par des polypeptides
JPH09505555A (ja) ＴＧＦ−βの活性を刺激および阻害する方法および組成物
US7772204B1 (en) Perlecan and growth factor for wound and cutaneous injury healing
US6500920B1 (en) Inhibitor of transforming growth factor β and A method of inhibiting the biological effects of transforming growth factor
Khouri et al. De novo generation of permanent neovascularized soft tissue appendages by platelet-derived growth factor.
EP0680334B1 (fr) Traitement d'ulceres gastro-intestinaux avec des morphogenes
Huber et al. Activation of human platelet-derived latent transforming growth factor-β 1 by human glioblastoma cells. Comparison with proteolytic and glycosidic enzymes
AU7591000A (en) Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
US20100215583A1 (en) Cell nucleus-entering compositions
Khan Chronic in vivo overexpression of TGF-B| 1 using a retroviral expression vector

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230417